Merck Serono Tops BMI's Pharmaceutical Research Investment Index For Q110

Compared with a selection of other drugmakers, Merck Serono spends the greatest proportion of its sales on research and development (R&D), according to BMI's Pharmaceutical Research Investment Index (PRII) for Q110. In the first quarter of this year, the Geneva-based firm spent US$377mn on developing new drugs. This equates to 20% of sales, resulting in a score of 0.20 on our

To read the full article, please choose one of the following options: